Taris begins dosing in second Phase II study with LiRIS

Clinical stage specialty pharmaceutical company Taris Biomedical has begun patient dosing in its second Phase II study with LiRIS, for the treatment of interstitial cystitis (IC).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news